Streetbeat News

Products Services

NTAP

NetApp (NASDAQ:NTAP) has renewed its strategic alliance and co-engineering partnership with DreamWorks Animation. NetApp will continue to be DreamWorks' preferred cloud data services provider, supporting both on-premises and cloud solutions. The partnership aims to optimize workflows in a hybrid cloud environment, decrease latency, and manage the studio's complex data requirements.

Portfolio Pulse from Happy Mohamed

July 11, 2023 | 12:08 pm

INTC

SNPS

Synopsys, Inc. (NASDAQ:SNPS) has announced its digital and custom design flows, powered by the Synopsys.ai™ full-stack AI-driven EDA suite, are certified for the Intel Foundry Services (IFS) Intel 16 process. The collaboration optimizes power, performance, and area for advanced chips targeting RF, storage, consumer, military, aerospace, and government applications. The collaboration also supports the U.S. Department of Defense's implementation of the Microelectronics Commons, a national network established under the CHIPS Act.

Portfolio Pulse from Happy Mohamed

July 11, 2023 | 12:08 pm

OCEA

Ocean Biomedical is developing a multivalent mRNA-based malaria vaccine that could target several stages in the malaria cycle. The company has also discovered a new therapeutic approach that could lead to a new class of anti-malarials. Ocean Biomedical holds multiple U.S. and global patents for both the vaccine and therapeutic approaches.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:06 pm

ZCMD

Zhongchao has partnered with Ximalaya to launch the first audio course series for cancer education. This partnership aims to provide accessible and comprehensive cancer education to the public.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:06 pm

CLDX

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has completed patient enrollment for its Phase 2 clinical study of barzolvolimab, a treatment for chronic spontaneous urticaria (CSU). Current treatment options for CSU are limited and there are no approved therapies for patients who do not respond to omalizumab.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:05 pm

AKTX

Akari Therapeutics has chosen the version of long-acting PAS-Nomacopan that it will advance into clinical trials. The company is on schedule for an IND submission in the first half of 2024 and the start of clinical trials in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:05 pm

SLGG

Super League (NASDAQ:SLGG) has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a new patent application related to the synchronization of live web streams. The patent is aimed at mitigating latency issues when combining multiple live streams, leading to high-quality productions.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:04 pm

MAIA

MAIA Biotechnology, Inc. (NYSE:MAIA) has announced updates on disease control data for its ongoing THIO-101 phase 2 trial for advanced Non-Small Cell Lung Cancer (NSCLC). Of the first 11 patients enrolled, 9 (82%) met the primary endpoint of disease control. All patients have previously failed 2 or more prior lines of treatment including an immune checkpoint inhibitor and platinum-based chemotherapy for advanced NSCLC.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:03 pm

SNCE

SYBX

Synlogic has chosen Science 37 to provide virtual clinical trial technology and services for its ongoing pivotal, Phase 3 trial of investigational drug labafenogene marselecobac for Phenylketonuria. The trial aims to study the effectiveness of the drug in PKU patients, with around 150 patients expected to be enrolled and monitored for up to three years. Science 37's platform will ensure data quality and consistency across all research sites.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:02 pm

CING

Biopharmaceutical company Cingulate Inc. (NASDAQ:CING) has announced positive top-line results from its Phase 3 adult trial of lead candidate CTx-1301 (dexmethylphenidate), a treatment for attention deficit/hyperactivity disorder (ADHD). The drug is being developed as a once-daily stimulant medication, pending approval from the U.S. Food and Drug Administration (FDA).

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:02 pm